A new drug in the treatment of familial hypercholesterolemia-lomitapide / 中国药学杂志

ABSTRACT

OBJECTIVE: To review the pharmacological actions and related clinical research about the efficacy and safety of lomitapide, which is a new kind of medication for cholesterol disorder-microsomal triglyceride transfer protein inhibitor. METHODS: The domestic and oversea pertinent literatures since 2007 were searched. RESULTS: Lomitapide can performe well in clinic effects and tolerance for homozygous familial hypercholesterolemia. CONCLUSION: Lomitapide can be an effective adjuvant for patients with homozygous familial hypercholesterolemia.